Mark Rothera, Chief Commercial Officer at PTC THERAPEUTICS, INC. (PTCT), sold 35,000 shares at $67.84 ($2.4M) on 2015-02-23, disclosed to the SEC on 2015-02-25.
Scheduled sale ($2.4M) by Chief Commercial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $62.69 | 5,000 | $313K | 13.2% |
| 2 | $63.66 | 5,000 | $318K | 13.4% |
| 3 | $64.72 | 3,000 | $194K | 8.2% |
| 4 | $67.84 | 10,000 | $678K | 28.5% |
| 5 | $67.70 | 1,000 | $68K | 2.8% |
| 6 | $73.49 | 11,000 |
| $808K |
| 34.0% |
| Total | $68.01 avg | 35,000 | $2.4M | 100% |
| Filing → |
| PTCT | SELL | 2015-03-18 | $820K | — | Filing → |
| PTCT | SELL | 2015-03-13 | $23K | — | Filing → |
| PTCT | SELL | 2015-01-22 | $180K | — | Filing → |